Vanguard Group’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$4.55B Sell
18,882,403
-158,037
-0.8% -$40.4M 0.07% 272
2025
Q3
$5.21B Buy
19,040,440
+293,515
+2% +$80.2M 0.08% 245
2025
Q2
$4.84B Buy
18,746,925
+253,223
+1% +$60.4M 0.08% 253
2025
Q1
$4.14B Buy
18,493,702
+320,240
+2% +$74.8M 0.07% 262
2024
Q4
$4.16B Buy
18,173,462
+160,590
+0.9% +$38.7M 0.07% 263
2024
Q3
$4.4B Buy
18,012,872
+112,570
+0.6% +$25.2M 0.08% 251
2024
Q2
$3.43B Buy
17,900,302
+130,536
+0.7% +$26.5M 0.07% 300
2024
Q1
$3.52B Buy
17,769,766
+26,309
+0.1% +$4.82M 0.07% 294
2023
Q4
$3.05B Buy
17,743,457
+173,635
+1% +$26.7M 0.07% 304
2023
Q3
$2.6B Sell
17,569,822
-6,801
-0% -$1.23M 0.06% 316
2023
Q2
$3.84B Buy
17,576,623
+60,070
+0.3% +$13.4M 0.09% 218
2023
Q1
$3.84B Buy
17,516,553
+1,010,935
+6% +$219M 0.1% 204
2022
Q4
$3.44B Buy
16,505,618
+243,774
+1% +$53.6M 0.09% 224
2022
Q3
$3.55B Buy
16,261,844
+199,805
+1% +$45.5M 0.1% 193
2022
Q2
$3.37B Buy
16,062,039
+194,582
+1% +$41.4M 0.09% 210
2022
Q1
$3.85B Buy
15,867,457
+254,208
+2% +$61.5M 0.09% 218
2021
Q4
$4.07B Buy
15,613,249
+55,424
+0.4% +$14.4M 0.09% 208
2021
Q3
$4.1B Buy
15,557,825
+142,021
+0.9% +$38.8M 0.1% 179
2021
Q2
$3.8B Sell
15,415,804
-70,054
-0.5% -$14.7M 0.09% 205
2021
Q1
$3B Buy
15,485,858
+46,014
+0.3% +$9.23M 0.08% 252
2020
Q4
$3.28B Sell
15,439,844
-204,669
-1% -$40.8M 0.1% 202
2020
Q3
$2.68B Sell
15,644,513
-348,334
-2% -$64.3M 0.09% 215
2020
Q2
$3.07B Sell
15,992,847
-137,607
-0.9% -$22.5M 0.11% 169
2020
Q1
$2.38B Buy
16,130,454
+340,161
+2% +$54.2M 0.1% 184
2019
Q4
$2.45B Buy
15,790,293
+143,324
+0.9% +$20.7M 0.08% 242
2019
Q3
$2.11B Buy
15,646,969
+319,737
+2% +$41.9M 0.08% 269
2019
Q2
$1.87B Buy
15,327,232
+212,459
+1% +$23.5M 0.07% 303
2019
Q1
$1.57B Buy
15,114,773
+249,539
+2% +$25.8M 0.06% 345
2018
Q4
$1.69B Buy
14,865,234
+297,429
+2% +$31.9M 0.08% 273
2018
Q3
$1.68B Buy
14,567,805
+69,129
+0.5% +$7.57M 0.07% 331
2018
Q2
$1.5B Buy
14,498,676
+38,860
+0.3% +$3.93M 0.06% 359
2018
Q1
$1.42B Buy
14,459,816
+178,525
+1% +$16.9M 0.06% 369
2017
Q4
$1.21B Buy
14,281,291
+141,115
+1% +$11.7M 0.05% 419
2017
Q3
$1.09B Buy
14,140,176
+2,225,505
+19% +$170M 0.05% 434
2017
Q2
$928M Buy
11,914,671
+378,964
+3% +$27.1M 0.05% 471
2017
Q1
$830M Buy
11,535,707
+508,392
+5% +$35.1M 0.04% 504
2016
Q4
$684M Buy
11,027,315
+341,179
+3% +$20.9M 0.04% 538
2016
Q3
$692M Sell
10,686,136
-993,189
-9% -$66.1M 0.04% 517
2016
Q2
$738M Buy
11,679,325
+1,114,598
+11% +$65.7M 0.05% 471
2016
Q1
$611M Buy
10,564,727
+320,341
+3% +$18.1M 0.04% 515
2015
Q4
$550M Buy
10,244,386
+212,360
+2% +$12M 0.04% 536
2015
Q3
$511M Buy
10,032,026
+160,672
+2% +$8.65M 0.04% 548
2015
Q2
$556M Buy
9,871,354
+353,609
+4% +$22.3M 0.04% 547
2015
Q1
$683M Buy
9,517,745
+606,909
+7% +$39.4M 0.05% 463
2014
Q4
$500M Buy
8,910,836
+33,419
+0.4% +$1.75M 0.04% 548
2014
Q3
$437M Sell
8,877,417
-79,605
-0.9% -$4.05M 0.03% 558
2014
Q2
$453M Buy
8,957,022
+127,127
+1% +$6.3M 0.04% 549
2014
Q1
$395M Buy
8,829,895
+218,725
+3% +$9.82M 0.03% 585
2013
Q4
$405M Buy
8,611,170
+55,224
+0.6% +$2.8M 0.04% 555
2013
Q3
$452M Buy
8,555,946
+93,050
+1% +$4.51M 0.04% 482
2013
Q2
$382M Buy
+8,462,896
New +$402M 0.04% 509

Other funds holding RMD

Vanguard Group's RMD Position: Q4 2025 in Review

Vanguard Group reduced its ResMed (RMD) stake by 0.83% in Q4 2025, selling an estimated $40.4M and leaving 18,882,403 shares worth $4.55B. The position accounts for 0.07% of the portfolio, ranked #272.

Vanguard Group first reported a position in RMD in Q2 2013 and has held it in 51 quarters since. The position peaked at $5.21B in Q3 2025. 945 funds tracked by Wall St. Rank hold RMD as of Q4 2025.

  • Vanguard Group held 18,882,403 shares of ResMed worth $4.55B as of Q4 2025.
  • Vanguard Group sold 158,037 ResMed shares in Q4 2025, an estimated $40.4M.
  • ResMed made up 0.07% of Vanguard Group's portfolio in Q4 2025, its #272 holding.
  • Vanguard Group first reported a position in ResMed in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's ResMed position peaked at $5.21B in Q3 2025.
  • 945 funds tracked by Wall St. Rank held ResMed as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.